Summit Therapeutics PLC annual free cash flow for fiscal TTM was -$431 million, a decrease of 79.6% from -$240 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Free Cash Flow (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow (FCF) | ($431M) | ($240M) | ($114M) | ($61M) | ($34M) | ($54M) | ($36M) | ($27M) | ($35M) | ($21M) | $15M | ($25M) | ($17M) | ($10M) | ($5M) | ($4M) | ($5M) | ($3M) | ($16M) | ($20M) | ($9M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Free Cash Flow (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow (FCF) | ($169M) | ($93M) | ($76M) | ($93M) | ($69M) | ($48M) | ($39M) | ($23M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More SMMT metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · EBITDA · Shares Outstanding
All SMMT financial statements → Interactive SMMT charts →
About TickerBase · Data methodology & sources · Privacy · Terms